Peer Review History

Original SubmissionNovember 18, 2021
Decision Letter - Abdul Qadir Syed, Editor

PONE-D-21-35752Differentially expressed microRNAs during the differentiation of muscle-derived stem cells into insulin-producing cells, a promoting role of microRNA-708-5p/STK4 axisPLOS ONE

Dear Dr. Ma,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

As you will see, both referees highlight the potential interest of the findings. However, they have raised a number of concerns and suggestions to improve the manuscript, or to strengthen the data and the conclusions drawn. As the reports are below, I will not detail them here, as we think all points need to be addressed. Given the constructive referee comments, we would like to invite you to revise your manuscript with the understanding that both referee concerns must be addressed in the revised manuscript and in a point-by-point response. Acceptance of your manuscript will depend on a positive outcome of a second round of review.

Please submit your revised manuscript by Feb 21 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Abdul Qadir Syed, PhD

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For more information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. 

In your revised cover letter, please address the following prompts:

a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially sensitive information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories.

We will update your Data Availability statement on your behalf to reflect the information you provide.

3. PLOS ONE now requires that authors provide the original uncropped and unadjusted images underlying all blot or gel results reported in a submission’s figures or Supporting Information files. This policy and the journal’s other requirements for blot/gel reporting and figure preparation are described in detail at https://journals.plos.org/plosone/s/figures#loc-blot-and-gel-reporting-requirements and https://journals.plos.org/plosone/s/figures#loc-preparing-figures-from-image-files. When you submit your revised manuscript, please ensure that your figures adhere fully to these guidelines and provide the original underlying images for all blot or gel data reported in your submission. See the following link for instructions on providing the original image data: https://journals.plos.org/plosone/s/figures#loc-original-images-for-blots-and-gels. 

  

In your cover letter, please note whether your blot/gel image data are in Supporting Information or posted at a public data repository, provide the repository URL if relevant, and provide specific details as to which raw blot/gel images, if any, are not available. Email us at plosone@plos.org if you have any questions.

4. Please include your full ethics statement in the ‘Methods’ section of your manuscript file. In your statement, please include the full name of the IRB or ethics committee who approved or waived your study, as well as whether or not you obtained informed written or verbal consent. If consent was waived for your study, please include this information in your statement as well.

5. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: No

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: No

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: No

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The objective of the study is well thought and executed.

But there are so many places in the manuscript which need to be improved.

There were no mention of which diabetes was studied here Type I or Type II?

Scientific English need to be used (centrifuging=centrifugation; 150 g=150xg) and reviewed carefully before submission. As line 224 mention: The separate and overlapping DEmiRNAs...... It may be refrain as "Unique and common" DEmiRNAs.... Last line mentioned "Left 11", it can be refrain as "remaining 11".

There are many places where sentences need to be reframed. Few sentences are repeated in Introduction and discussion. Every time Scale bar has been mentioned as separate sentence without making a sentence, which need to be corrected. p-values either be given in sentence or in parentheses.

What is RPMI? Is this a growth medium or Institute?

nictinamide=nicotinamide.

Version and references need to be provided for used Softwares and databases.

Methods: What were the analysis parameters used for processing of Raw sequence data and quality passed data?

Wild-type STK4 (STK4-WT) and the mutant 141 STK4 (STK4-MT) were cloned into pGL3 alkaline luciferase vector. Explain Mutation experiment.

Line 171: performed at least three independent repetitions. Is this assumption or confirmation regarding replicates?

Results:

Sequencing: No result has been mentioned about sequencing (Data obtained, processed in terms of reads and quality). pls provide this detail. What

Line 193: These two markers; Which are these two markers? Explain.

Line 208: Pls provide Figure number for heatmap.

There were 7145 target genes identified but only mention of 1655 for GO term analysis, what about other genes? Pls explain how these GO terms (12 biological process, 6 cellular components and 2 molecular functions) are related to IPCs differentiation.

Venn diagram and heatmap and bar charts are not visible, high quality figures may be submitted.

Line 311: Emerging data suggest that miRNAs act as a pivotal role in IPCs differentiation; "miRNAs play a pivotal role". Refrain the sentence.

Line 315: These researchers; Which researchers referred here?

Line 322: The results showed that these target genes were mainly related to cellular process and signal transduction. "No mention of Which cellular process and signal transduction." Explain and give details.

Line 334: STK4 exerts a regulatory effect on IPCs differentiation via phosphorylating YAP1....... Which kind of regulatory effect "Positive or negative"? Conclusion was based on this comparison and effect was not explained in the manuscript.

Reviewer #2: In the current study, the authors have tried to show the importance and involvement of miR-708-5p during differentiation of MDSCs into insulin producing cells. Although the study is important, experiments needs to be revised properly with proper controls.

1. Most of the experiments involve the expression of proteins by immunofluorescence studies. However, they lack proper control and comparisons. In Fig.1 the MDSCs marker expressions needs to be compared with the 0h cells. Likewise, in Fig.2, the insulin / c-peptide expression can be compared at each stage.

2. Similarly, the experiments involving addition of miR-708-5p mimic needs untreated cells as wells as NC-miRNA as controls.

3. The image quality needs to be improved throughout. The flow plots are not possible to read.

4. Authors need to explain about the STK4-Mut in detail. Is it having a mutated miR-708 binding site? If yes the details needs to be provided.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Ram Nageena Singh

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Revision 1

Thanks for giving us the opportunity to submit a revised draft of the manuscript “Differentially expressed microRNAs during the differentiation of muscle-derived stem cells into insulin-producing cells, a promoting role of microRNA-708-5p/STK4 axis” for publication in the Journal of PLOS ONE. We appreciate the time and effort that editors and reviewers dedicated to providing feedback on our manuscript and are grateful for the insightful comments on and valuable improvements to our paper. We have incorporated most of the suggestions made by the reviewers. Those revisions are highlighted in the manuscript with tracked changes. Please see below, in blue, for a point-by-point response to the reviewers’ comments and concerns.

Reviewer #1: The objective of the study is well thought and executed.

But there are so many places in the manuscript which need to be improved.

There were no mention of which diabetes was studied here Type I or Type II?

R: This study is not specific to the type of diabetes. Stem cell therapy is a promising therapeutic approach for both Type I and Type II diabetes. Thus, the type of diabetes is not specified in this study.

Scientific English need to be used (centrifuging=centrifugation; 150 g=150xg) and reviewed carefully before submission.

R: Thanks for pointing this out. We have reviewed this manuscript carefully and revised these non-standard writing.

As line 224 mention: The separate and overlapping DEmiRNAs...... It may be refrain as "Unique and common" DEmiRNAs.... Last line mentioned "Left 11", it can be refrain as "remaining 11".

R: Thanks for pointing this out. We have modified these words as you suggested.

There are many places where sentences need to be reframed. Few sentences are repeated in Introduction and discussion.

R: Thanks for your suggestion. We have revised sentences that were repeated in the Discussion with the Introduction.

Every time Scale bar has been mentioned as separate sentence without making a sentence, which need to be corrected. p-values either be given in sentence or in parentheses.

R: Thanks for pointing this out. We have revised the “Scale bar = 100 or 200 μm” into a sentence “Scale bar is 100 or 200 μm” in the Figure legends. P-values have been given in sentence, e.g., “***P < 0.001 compared with the Control.”.

What is RPMI? Is this a growth medium or Institute?

R: RPMI is a growth medium and its full name has been modified to the Roswell Park Memorial Institute (RPMI) medium in the Methods section.

nictinamide=nicotinamide.

R: The word “nictinamide” has been revised to “nicotinamide”.

Version and references need to be provided for used Softwares and databases.

R: Thanks for pointing this out. The versions and references for used softwares and databases have been added to the Methods section.

Methods: What were the analysis parameters used for processing of Raw sequence data and quality passed data?

R: The high-quality sequencing data were screened according to the criteria as follows: 1) Remove the 3' linker sequence in the reads, and remove the reads without insert fragments due to the self-ligation of the linker; 2) Remove the reads with low sequencing quality in 3'-base (the quality value is less than 20); 3) Remove reads containing unknown base N; 4) Choose reads with length between 18nt and 32nt. These analysis parameters have been added to the Methods section.

Wild-type STK4 (STK4-WT) and the mutant 141 STK4 (STK4-MT) were cloned into pGL3 alkaline luciferase vector. Explain Mutation experiment.

R: STK4-MT was established via mutating the putative binding site of miR-708-5p in STK4 3’-UTR, which has been described in the Methods section.

Line 171: performed at least three independent repetitions. Is this assumption or confirmation regarding replicates?

R: The replicate determination is to confirm the results.

Results:

Sequencing: No result has been mentioned about sequencing (Data obtained, processed in terms of reads and quality). pls provide this detail. What

R: Thanks for pointing this out. The data acquisition and processing about sequencing have been provided in the Methods section. In the Results section, we mainly described the obtained differentially expressed miRNAs from sequencing.

Line 193: These two markers; Which are these two markers? Explain.

R: These two markers are insulin and C-peptide that have been explained in the Results section.

Line 208: Pls provide Figure number for heatmap.

R: The heatmap is in Figure 3B, which has been provided in the Results section.

There were 7145 target genes identified but only mention of 1655 for GO term analysis, what about other genes? Pls explain how these GO terms (12 biological process, 6 cellular components and 2 molecular functions) are related to IPCs differentiation.

R: In this study, we mainly explored the KEGG pathways involved in metabolism, genetic information processing, environmental information processing, cellular processes, organismal systems, and human diseases. A total of 1655 genes were enriched in these pathways, therefore, we mentioned 1655 target genes for KEGG pathway analysis in this manuscript. For GO terms analysis, most of GO terms were closely related to cellular process and biological regulation that play important roles during IPCs differentiation. The association between GO terms and IPCs differentiation has been explained in the Results section.

Venn diagram and heatmap and bar charts are not visible, high quality figures may be submitted.

R: Thanks for pointing this out. We have re-provided these images with high resolution (300 dpi).

Line 311: Emerging data suggest that miRNAs act as a pivotal role in IPCs differentiation; "miRNAs play a pivotal role". Refrain the sentence.

R: We have revised the “miRNAs act as a pivotal role” to "miRNAs play a pivotal role" in the Discussion section as you suggest.

Line 315: These researchers; Which researchers referred here?

R: “These researchers” means the previous studies mentioned in the manuscript. We have modified “These researchers” to “These previous studies” in the Discussion section.

Line 322: The results showed that these target genes were mainly related to cellular process and signal transduction. "No mention of Which cellular process and signal transduction." Explain and give details.

R: Cellular process and signal transduction includes cell growth and death, apoptosis signaling pathway, insulin/IGF pathway-MAPK cascade, etc. That has been added in the Discussion section.

Line 334: STK4 exerts a regulatory effect on IPCs differentiation via phosphorylating YAP1....... Which kind of regulatory effect "Positive or negative"? Conclusion was based on this comparison and effect was not explained in the manuscript.

R: STK4 may exert a negative regulatory effect on IPCs differentiation, which has been revised in the Discussion section. There is direct evidence for the effect of STK4 on IPCs differentiation in this study, which will be further confirmed in subsequent investigation. In this study, we mainly focus on the role of miR-708-5p in IPCs differentiation.

Reviewer #2: In the current study, the authors have tried to show the importance and involvement of miR-708-5p during differentiation of MDSCs into insulin producing cells. Although the study is important, experiments needs to be revised properly with proper controls.

1. Most of the experiments involve the expression of proteins by immunofluorescence studies. However, they lack proper control and comparisons. In Fig.1 the MDSCs marker expressions needs to be compared with the 0h cells. Likewise, in Fig.2, the insulin / c-peptide expression can be compared at each stage.

R: Thanks for your professional suggestion. The experimental design of this study referred to the previous research by Xu et al. (2019) (PMID: 30767782). The comparisons of the results in Fig. 1 have been revised as you suggest. In Fig. 2, the insulin/C-peptide expression of MDSCs-derived IPCs was compared to MDSCs without differentiation.

2. Similarly, the experiments involving addition of miR-708-5p mimic needs untreated cells as wells as NC-miRNA as controls.

R: Thanks for your professional suggestion. The experimental design of this study referred to the previous research by Xu et al. (2019) (PMID: 30767782), which can provide enough evidence to confirm the effect of miR-708-5p.

3. The image quality needs to be improved throughout. The flow plots are not possible to read.

R: Thanks for pointing this out. We have improved images with high resolution.

4. Authors need to explain about the STK4-Mut in detail. Is it having a mutated miR-708 binding site? If yes the details needs to be provided.

R: STK4-MT was established via mutating the putative binding site of miR-708-5p in STK4 3’-UTR, which has been described in the Methods section.

Attachments
Attachment
Submitted filename: Response to Reviewers.docx
Decision Letter - Abdul Qadir Syed, Editor

PONE-D-21-35752R1Differentially expressed microRNAs during the differentiation of muscle-derived stem cells into insulin-producing cells, a promoting role of microRNA-708-5p/STK4 axisPLOS ONE

Dear Dr. Ma,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Specifically, there is still one comment which was not addressed in the revised manuscript. I highly suggest that author should address this comment in the final version of manuscript. 

Please submit your revised manuscript by May 02 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Abdul Qadir Syed, PhD

Academic Editor

PLOS ONE

Journal Requirements:

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

Additional Staff Editor Comments (if provided): PLOS ONE does not provide copyediting or proofs of accepted manuscripts. We therefore recommend that you carefully review your manuscript and correct any language errors at this time.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: (No Response)

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: There is still one comment which need to be addressed.

Statistical Analysis:

Line 182: Each experiment was performed at least three independent repetitions.

This sentence reflects that Authors were confirmed about number of replicates. Why "at least"? Why not that "All the experiments were performed with 3 replicates"?

Pls revise the sentence.

Reviewer #2: The authors have answered all the comments satisfactorily. Now, it can be considered for publication.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Ram Nageena Singh

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Revision 2

Thanks for giving us the opportunity to submit a revised draft of the manuscript “Differentially expressed microRNAs during the differentiation of muscle-derived stem cells into insulin-producing cells, a promoting role of microRNA-708-5p/STK4 axis” for publication in the Journal of PLOS ONE. We appreciate the time and effort that editors and reviewers dedicated to providing feedback on our manuscript and are grateful for the insightful comments on and valuable improvements to our paper. We have incorporated most of the suggestions made by the reviewers. Those revisions are highlighted in the manuscript with tracked changes. Please see below, in blue, for a point-by-point response to the reviewers’ comments and concerns.

Journal Requirements:

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

R: We have carefully reviewed the reference cited in this manuscript, and ensure that it is complete and correct.

Additional Staff Editor Comments (if provided): PLOS ONE does not provide copyediting or proofs of accepted manuscripts. We therefore recommend that you carefully review your manuscript and correct any language errors at this time.

R: We have carefully reviewed this manuscript, and corrected language errors.

Reviewer #1: There is still one comment which need to be addressed.

Statistical Analysis:

Line 182: Each experiment was performed at least three independent repetitions.

This sentence reflects that Authors were confirmed about number of replicates. Why "at least"? Why not that "All the experiments were performed with 3 replicates"?

Pls revise the sentence.

R: Thanks for pointing this out. We have revised the sentence “Each experiment was performed at least three independent repetitions.” to “All the experiments were performed with three independent repetitions.” in line 181.

Reviewer #2: The authors have answered all the comments satisfactorily. Now, it can be considered for publication.

R: Authors appreciate reviewer’s valuable comments and approval for publication.

Attachments
Attachment
Submitted filename: Response to Reviewers.docx
Decision Letter - Abdul Qadir Syed, Editor

Differentially expressed microRNAs during the differentiation of muscle-derived stem cells into insulin-producing cells, a promoting role of microRNA-708-5p/STK4 axis

PONE-D-21-35752R2

Dear Dr. Ma, 

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Abdul Qadir Syed, PhD

Academic Editor

PLOS ONE

Formally Accepted
Acceptance Letter - Abdul Qadir Syed, Editor

PONE-D-21-35752R2

Differentially expressed microRNAs during the differentiation of muscle-derived stem cells into insulin-producing cells, a promoting role of microRNA-708-5p/STK4 axis

Dear Dr. Ma:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Abdul Qadir Syed

Academic Editor

PLOS ONE

Open letter on the publication of peer review reports

PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.

We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.

Learn more at ASAPbio .